Research ExplorerPublicationsJanus kinase inhibitors and allogeneic stem cell transplanta...

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis

Standard

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. / Gupta, Vikas; Gotlib, Jason; Radich, Jerald P; Kröger, Nicolaus M; Rondelli, Damiano; Verstovsek, Srdan; Deeg, H Joachim.

In: BIOL BLOOD MARROW TR, Vol. 20, No. 9, 01.09.2014, p. 1274-81.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gupta, V, Gotlib, J, Radich, JP, Kröger, NM, Rondelli, D, Verstovsek, S & Deeg, HJ 2014, 'Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis', BIOL BLOOD MARROW TR, vol. 20, no. 9, pp. 1274-81. https://doi.org/10.1016/j.bbmt.2014.03.017

APA

Gupta, V., Gotlib, J., Radich, J. P., Kröger, N. M., Rondelli, D., Verstovsek, S., & Deeg, H. J. (2014). Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. BIOL BLOOD MARROW TR, 20(9), 1274-81. https://doi.org/10.1016/j.bbmt.2014.03.017

Vancouver

Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S et al. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. BIOL BLOOD MARROW TR. 2014 Sep 1;20(9):1274-81. https://doi.org/10.1016/j.bbmt.2014.03.017

Bibtex

@article{1d1b4ccf38a94492a242b4f341dd49f3,
title = "Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis",
abstract = "Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis, collectively referred to as myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy with proven curative potential. However, most patients with MF are in their 6th or 7th decade of life, and only some of these patients have been considered suitable transplantation candidates. The development of reduced-intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a growing number of older patients. The availability of Janus Kinase (JAK) 1/2 inhibitors allows clinicians to provide symptom relief and improved quality of life for MF patients. These drugs may also affect the decision regarding, in particular, the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in patients who are transplantation candidates and determine their role before and, possibly, after transplantation. The identification of indications for the use of JAK1/2 inhibitors in the context of transplantation may lead to new therapeutic strategies for patients with MF.",
author = "Vikas Gupta and Jason Gotlib and Radich, {Jerald P} and Kr{\"o}ger, {Nicolaus M} and Damiano Rondelli and Srdan Verstovsek and Deeg, {H Joachim}",
note = "Copyright {\textcopyright} 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = sep,
day = "1",
doi = "10.1016/j.bbmt.2014.03.017",
language = "English",
volume = "20",
pages = "1274--81",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis

AU - Gupta, Vikas

AU - Gotlib, Jason

AU - Radich, Jerald P

AU - Kröger, Nicolaus M

AU - Rondelli, Damiano

AU - Verstovsek, Srdan

AU - Deeg, H Joachim

N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis, collectively referred to as myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy with proven curative potential. However, most patients with MF are in their 6th or 7th decade of life, and only some of these patients have been considered suitable transplantation candidates. The development of reduced-intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a growing number of older patients. The availability of Janus Kinase (JAK) 1/2 inhibitors allows clinicians to provide symptom relief and improved quality of life for MF patients. These drugs may also affect the decision regarding, in particular, the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in patients who are transplantation candidates and determine their role before and, possibly, after transplantation. The identification of indications for the use of JAK1/2 inhibitors in the context of transplantation may lead to new therapeutic strategies for patients with MF.

AB - Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis, collectively referred to as myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy with proven curative potential. However, most patients with MF are in their 6th or 7th decade of life, and only some of these patients have been considered suitable transplantation candidates. The development of reduced-intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a growing number of older patients. The availability of Janus Kinase (JAK) 1/2 inhibitors allows clinicians to provide symptom relief and improved quality of life for MF patients. These drugs may also affect the decision regarding, in particular, the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in patients who are transplantation candidates and determine their role before and, possibly, after transplantation. The identification of indications for the use of JAK1/2 inhibitors in the context of transplantation may lead to new therapeutic strategies for patients with MF.

U2 - 10.1016/j.bbmt.2014.03.017

DO - 10.1016/j.bbmt.2014.03.017

M3 - SCORING: Journal article

C2 - 24680977

VL - 20

SP - 1274

EP - 1281

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 9

ER -